• About
    • Awards
    • History
    • Leadership
    • Board of Directors
    • Investors and Partners
  • Pipeline
    • Cefepime-Taniborbactam
    • Ceftibuten-Ledaborbactam Etzadroxil
    • PBP Inhibitor
  • Publications
    • Manuscripts
    • Conference Presentations
  • News & Events
    • Press Releases
    • In the News
    • Events
  • Careers
    • Open Positions
    • #venatorxcares
  • Contact
Publications
  • Publications
  • Manuscripts
  • Conference Presentations

Manuscripts

Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States
Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection
MORE MANUSCRIPTS

Conference Presentations

Susceptibility Profiles of Baseline Gram-negative Pathogens from CERTAIN-1, a Phase 3 Study comparing Cefepime-taniborbactam to Meropenem in Adultswith Complicated Urinary Tract Infection (cUTI)
Validation of Cefepime-Taniborbactam MIC Antimicrobial Susceptibility Test for MicroScan Dried Gram-Negative MIC Panels from a Multicenter Assessment of Enterobacterales and Pseudomonas aeruginosa
Activity of Cefepime-Taniborbactam (FTB) Against Enterobacterales and P. aeruginosa Collected Globally in 2018-2021 Stratified by β-lactamase Carriage
Antimicrobial Activity of Cefepime in Combination with Taniborbactam Against Resistant Clinical Isolates of Enterobacterales from 2018-2021 Global Surveillance
MORE CONFERENCE PRESENTATIONS
  • ©2023 Venatorx Pharmaceuticals, Inc.
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
  • Sitemap
You are using a browser that is not supported. Please consider changing your browser